Erika Paige Hamilton (Erika Hamilton, Erika P Hamilton, Erica Hamilton)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 61

Top Topics

Epidermal Growth Factor Receptor

Endoplasmic Reticulum

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature medicine

Future oncology (London, England)

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andres Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoine Italiano, Kevin M Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Juric
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder, Anthony W Tolcher, Naoto Tada Ueno, S Lindsey Davis, Douglas W Orr, Erika Paige Hamilton, Manish R Patel, Alexander I Spira, Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R Barkund, Haiying Zhou, Aleksandr Pankov, Wayne Kong, Nadine S Jahchan, Erica L Jackson, Jessica D Sun, Melissa R Junttila, Pratik S Multani, Anneleen Daemen, Edna Chow-Maneval, Pamela N Munster
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Sarina A Piha-Paul, Shane A Olwill, Erika Paige Hamilton, Anthony W Tolcher, Paula R Pohlmann, Stephen V Liu, Cornelia Wurzenberger, Laura-Carolin Hasenkamp, Eva-Maria Hansbauer, Rachna T Shroff, Sara Alsterlind Hurvitz, Anuradha Krishnamurthy, Amita Patnaik, Noah M Hahn, Raman Kumar, Manuela Duerr, Markus Zettl, Kayti Aviano, Louis Matis, Ingmar Bruns, Geoffrey Y Ku
A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances M Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika Paige Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey A Tryakin, Irfan Cicin, Laura Testa, Patrick Neven, Jens Huober, Zhi-Ming Shao, Ran Wei, Valérie André, Maria Munoz, Belen San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen R D Johnston
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Komal L Jhaveri, Elgene Lim, Rinath M Jeselsohn, Cynthia X Ma, Erika Paige Hamilton, Cynthia Osborne, Manali Bhave, Peter A Kaufman, J Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei-Chung Wang, Jessica J Tao, Seock-Ah Im, Kathleen K Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joo Hyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian M Smyth, Muralidhar Beeram
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Erika Paige Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Jason John Luke, Manish R Patel, George R Blumenschein, Erika Paige Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakeela W Bahadur, Andrew Weickhardt, Adam S Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L Kindler, Bradley J Sumrow, Patrick Kaminker, Francine Z Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun, Paul A Moore
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nature medicine (2023)
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Lucian DiPietro, Adam Frost, Fabrizio Giordanetto, Erika Paige Hamilton, Katherine Harris, Michael J Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R LaRochelle, Andre Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M Mader, Brenton G Mar, Iain Martin, Thomas H McLean, Klaus Michelsen, Yakov Pechersky, Erika G Puente, Ramin Samadani, Alison M Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R Williams, Hongtao Zeng, W Patrick Walters, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Brian K Shoichet, Pascal D Fortin, D Randal Kipp
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer discovery (2023)
Erika Paige Hamilton, Judy S Wang, Amit M Oza, Manish R Patel, Susanna V Ulahannan, Todd M Bauer, Janet L Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova, Ganesh Moorthy, Maureen M Hattersley, Gillian M Littlewood, Patrick D Mitchell, Jamal Saeh, Gayle P Pouliot, Kathleen M Moore
First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. Molecular cancer therapeutics (2023)
Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, Matthew Young, Thomas Powles, Erika Paige Hamilton
Rise of Antibody-Drug Conjugates: The Present and Future. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Mythili Shastry, Erika Paige Hamilton
Novel Estrogen Receptor-Targeted Agents for Breast Cancer. Current treatment options in oncology (2023)
Linda R Duska, Dmitriy Zamarin, Erika Paige Hamilton, Amit M Oza, Gini F Fleming, Alexander I Spira, Oladapo O Yeku, Debra L Richardson, Jackie Walling, Kerry Inokuchi, Bernice Matusow, Gideon Bollag, Elizabeth M Swisher
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO precision oncology 7 (2023)
Ignace Vergote, José Alejandro Pérez-Fidalgo, Erika Paige Hamilton, Giorgio Valabrega, Toon Van Gorp, Jalid Sehouli, David Cibula, Tally Levy, Stephen Welch, Debra L Richardson, Eva M Guerra, Giovanni Scambia, Stéphanie Henry, Pauline Wimberger, David Scott Miller, Jaroslav Klat, Jerónimo Martínez-Garcia, Francesco Raspagliesi, Bhavana Pothuri, Ignacio Romero, Alice Bergamini, Brian Slomovitz, Fabienne Schochter, Estrid Høgdall, Lorena Fariñas-Madrid, Bradley J Monk, Dayana Michel, Michael G Kauffman, Sharon Shacham, Mansoor Raza Mirza, Vicky Makker, null null
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Matthew P Goetz, Erika Paige Hamilton, Mario Campone, Sara Alsterlind Hurvitz, Javier Cortes, Stephen R D Johnston, Antonio Llombart, Peter A Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M Jansen, Lacey M Litchfield, Miguel Martin
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Paige Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do Youn Oh, Alicia F C Okines, David M O'Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas Eldridge Stinchcombe, Tanios S Bekaii-Saab
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mythili Shastry, Marilyn E Holt, Andrew J McKenzie, Erika Paige Hamilton
Breaking Barriers: Integrating Germline Testing With Oncology Care. JCO oncology practice (2023)
Sandra M Swain, Mythili Shastry, Erika Paige Hamilton
Targeting HER2-positive breast cancer: advances and future directions. Nature reviews. Drug discovery (2022)
Amita Patnaik, Erika Paige Hamilton, Yan Xing, Drew W Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers 14 (20) (2022)
Emma G Sturgill, Amanda Misch, Rebecca Lachs, Carissa C Jones, Dan Schlauch, Suzanne F Jones, Mythili Shastry, Denise A Yardley, Howard A Burris, David R Spigel, Erika Paige Hamilton, Andrew J McKenzie
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. JCO precision oncology 5 (2022)
Bolivar Arboleda-Osorio, Rupert Bartsch, Evandro de Azambuja, Erika Paige Hamilton, Nadia Harbeck, Jennifer R Klemp, Michael Knauer, Sherko Kuemmel, Reshma L Mahtani, Florian Scotté, Cynthia Villarreal Garza, Antonio Wolff
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. The oncologist 27 (9) (2022)
Timothy Anthony Yap, Erika Paige Hamilton, Todd M Bauer, Ecaterina E Ileana Dumbrava, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K Lin, Jenn Habeck, Heidi Giordano, Geoffrey I Shapiro
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO precision oncology 6 (2022)
Laura M Spring, Hyo Han, Minetta C Liu, Erika Paige Hamilton, Hanna Irie, Cesar A Santa-Maria, James Reeves, Peng Pan, Ming Shan, Yongqiang Tang, Julie R Graham, Sebastien Hazard, Leif W Ellisen, Steven Jay Isakoff
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature cancer 3 (8) (2022)
Siqing Fu, Bradley R Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R Wendel Naumann, Robert M Wenham, Rafael D Rosengarten, Laura Benjamin, Erika Paige Hamilton, Kathleen M Moore
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)
Erika Paige Hamilton, Javier Cortes, Ozgur Ozyilkan, Shin-Cheh Chen, Katarina Petrakova, Aleksey Manikhas, Guy Jerusalem, Roberto Hegg, Jens Huober, Wei Zhang, Yanyun Chen, Miguel Martin
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. Breast cancer research and treatment 195 (1) (2022)
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Paige Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortes, Jens Huober, Andrew Wardley, Sara M Tolaney, Irfan Cicin, Ian C Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O'Shaughnessy, Priya Rastogi, null null
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (34) (2020)